Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MK-1484 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on MK-1484, a putative IL-2 agonist (Apr 2023). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MK-1484 | MK 1484|MK1484 | Limited information is currently available on MK-1484, a putative IL-2 agonist (Apr 2023). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05382325 | Phase I | MK-1484 MK-1484 + Pembrolizumab | A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) | Active, not recruiting | USA | NLD | ISR | CAN | 0 |